AIM ImmunoTech Inc.
Close on Oct 19, 2026
- Market cap
- $2.79M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 10, 2026 | Before market open | – | $-0.43 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 19, 2026 | Before market open | – | – | – |
| Q1 FY2020 Ended Mar 31, 2020 | Apr 16, 2020 | During market hours | – | – | – |
| Q3 FY2019 Ended Sep 30, 2019 | Oct 7, 2019 | Before market open | – | – | – |
| Q2 FY2017 Ended Jun 30, 2017 | Aug 15, 2017 | Before market open | – | – | – |
| Q1 FY2017 Ended Mar 31, 2017 | Apr 3, 2017 | During market hours | – | – | – |
| Q3 FY2016 Ended Sep 30, 2016 | Nov 15, 2016 | During market hours | – | – | – |
| Q2 FY2016 Ended Jun 30, 2016 | Aug 15, 2016 | During market hours | – | – | – |
| Q1 FY2016 Ended Mar 31, 2016 | May 16, 2016 | During market hours | – | – | – |
| Q4 FY2015 Ended Dec 31, 2015 | Mar 30, 2016 | Before market open | – | – | – |
Press releases
Announcements AIM ImmunoTech filed with the SEC
Is Force Protection: Ready Today, Prepared for Tomorrow
Regulation FD disclosure · EX-99.1 to Form 8-K
DRAFT NOT FOR IMMEDIATE RELEASE
Results of operations · EX-99.1 to Form 8-K
AIM ImmunoTech Regains NYSE American Compliance,
Other events · EX-99.1 to Form 8-K
ImmunoTech Announces $2.65 Million Financing Priced At-Market under NYSE American Rules
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ImmunoTech Releases Virtual Investor ‘What This Means’ Video Segment Discussing Ampligen’s Potential in Ebola Virus
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.2 to Form 8-K
Regulation FD disclosure · EX-99.2 to Form 8-K
ImmunoTech Announces Significant Increase in Stockholder Equity and Extension of Promissory Note Maturity Date to June 2027, Enhancing
Material agreement · Results of operations · New financial obligation · Regulation FD disclosure · EX-99.1 to Form 8-K
ImmunoTech Posts Virtual Investor Key Opinion Leader Segment Spotlighting Ampligen Breakthrough Data in Pancreatic Cancer
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Year-End Interim Clinical Progress Update
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ImmunoTech Reports Positive Year-End Interim Clinical Progress from Phase 2 Study
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
of Change and Modification of Class E Common Stock Purchase Warrants
Regulation FD disclosure · EX-99.1 to Form 8-K
of Change and Modification of Class F Common Stock Purchase Warrants
Regulation FD disclosure · EX-99.2 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
ImmunoTech Announces Closing of $8.0 Million Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
ImmunoTech Reports Positive Mid-year Safety and Efficacy Data from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination
Other events · EX-99.1 to Form 8-K
Mid-Year Interim Clinical Progress Update
Other events · EX-99.2 to Form 8-K
ImmunoTech Announces NYSE American Notice of Noncompliance With Minimum Stockholders’ Equity Requirements
Listing notice · Other events · EX-99.1 to Form 8-K
ImmunoTech Announces 1-for-100 Reverse Stock Split
Listing notice · Charter or bylaw amendment · Other events · EX-99.1 to Form 8-K
ImmunoTech Announces NYSE American Removal of Trading Suspension
Listing notice · Charter or bylaw amendment · Other events · EX-99.2 to Form 8-K
ImmunoTech Announces NYSE American Notice of Delisting and Appeal
Listing notice · Other events · EX-99.1 to Form 8-K
ImmunoTech Announces NYSE American Acceptance of Plan to Regain Listing Compliance
Other events · EX-99.1 to Form 8-K
ImmunoTech Releases Virtual Investor “What This Means Segment”
Other events · EX-99.1 to Form 8-K
ImmunoTech announces that it will not proceed with an offering pursuant to its Registration Statement on Form S-1 until after it files
Other events · EX-99.1 to Form 8-K
DRAFT NOT FOR IMMEDIATE RELEASE
Other events · EX-99.1 to Form 8-K
Medical Center Safety Committee Grants Approval to Proceed with Phase 2 Study of Ampligen® and Imfinzi as a Potential Combination
Other events · EX-99.1 to Form 8-K
ImmunoTech Announces Notification of Noncompliance with
Listing notice · Other events · EX-99.1 to Form 8-K
ImmunoTech Announces Cash Conservation Plan
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ImmunoTech Announces Pricing of $2.0 Million Registered Direct Offering
Material agreement · Unregistered share sale · Other events · EX-99.1 to Form 8-K
ImmunoTech Reports Positive Topline Results from Phase 2 Study Evaluating Ampligen ® for the Treatment of Post-COVID Conditions
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
ImmunoTech Announces Open Enrollment for Phase 1b/2 Study Evaluating
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
EX-99.1 to Form 8-K
Regulation FD disclosure · EX-99.1 to Form 8-K
ImmunoTech Selected to Present at the 3 rd Annual Marie Sklodowska-Curie Symposium on Cancer Research and Care
Regulation FD disclosure · EX-99.2 to Form 8-K
to Purported Notice of Stockholder Intent to Nominate Individuals for Election as Director at the 2023 Annual Meeting of Stockholders
Regulation FD disclosure · EX-99.1 to Form 8-K
ImmunoTech Rejects Director Nomination Notice from Activist Group Due to Numerous Material Defects, Omissions and False and Misleading
Regulation FD disclosure · EX-99.2 to Form 8-K